ArticleThe world journal of men's health2021
Male Breast Cancer: A Comparative Analysis from the National Cancer Database.
Article in The world journal of men's health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial.Breast cancer research and treatment · 2022Trial
- Rurality and Income on Breast Cancer Outcomes: An Analysis of the SEER Database.Annals of surgical oncology · 2026Article
- Sex Disparities in Breast Cancer Survival According to Clinical Treatment Score Post-5 Years (CTS5) Risk Stratification.Cancer research and treatment · 2026Article
- Sex-Based Differences in Noncommunicable Diseases in Older Adults: Raising the Profile of Older Females.Journal of the American Geriatrics Society · 2026Article
- Pulmonary Tumor Thrombotic Microangiopathy in a Patient With Male Breast Cancer: A Report of a Rare Case.Cureus · 2026Article
- Racial and ethnic disparities and socioeconomic determinants of male breast cancer mortality in the United States.Breast cancer research and treatment · 2025Article
- Clinical, therapeutic and prognostic differences between male and female patients with breast cancer-a comparison of 2510 men and 307,634 women in a registry-based study in Germany.Journal of cancer research and clinical oncology · 2025Article
- Clinical aspect of male breast cancer: a burgeoning and unaddressed issue.Molecular biology reports · 2025Review
- Comprehensive review of male breast cancer: Understanding a rare condition.Oncology research · 2025Review
- Unveiling the comorbidity burden of male breast cancer.Scientific reports · 2024Observational
- Male breast cancer: a 32-year retrospective analysis in radiation therapy referral center in northern Iran.Annals of medicine and surgery (2012) · 2024Article
- Article
- Male Breast Cancer: An Updated Review of Patient Characteristics, Genetics, and Outcome.International journal of breast cancer · 2024Review
- Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan.Breast cancer (Tokyo, Japan) · 2022Article
- Male triple negative axillary accessory breast cancer-a case report.Translational cancer research · 2022Article
- Characteristics of metastasis and survival between male and female breast cancer with different molecular subtypes: A population-based observational study.Cancer medicine · 2022Observational
- Hormone receptor-positive breast cancer and black race: does sex matter?Breast cancer research and treatment · 2021Article
- Characteristics, Treatment, and Survival of Male Breast Cancer: A 21-year Retrospective Analysis at a Community Academic Institute in Central Illinois.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeBreast cancer (BC) in males accounts for <0.5% of all male cancer diagnoses and ~1% of all BCs in the United States. We sought to describe clinicopathologic characteristics among male and female BC patients and differences in overall survival (OS) through the National Cancer Database over 13 years (2004-2016). MATERIALS AND
methodsSecondary to the 1:99 ratio of male to female BC cases, we randomly selected female cases for equal comparison to males cases by diagnosis year. Chi-square and t-tests compared demographic and tumor characteristics. OS was examined using Kaplan-Meier survival analysis.
resultsAmong the ~2.7 million BC patients, 9 per 1,000 BCs were in males, the rate remained similar over time. The mean (SD) age was 64.9±13.0 years for males and 60.7±13.6 years for females. Most of the male BC cases were white (non-Hispanic) (n=19,015 [80.2%]), clinical stage I (n=7,353 [32.1%]) or stage II disease (n=7,923 [34.6%]), and tumors were moderate or poorly differentiated (84.5%). Males exhibited more comorbidities, presented with a larger proportion of disease, and decreased OS (p<0.005) than females. Male OS was >10% lower at 5-years and nearly 20% lower at 10-years for males. More males had primary BC tumors under the nipple; the 10-year OS rate for this site was 48.8%.
conclusionsThis study reports clinicopathologic characteristics of a large cohort of male BC. Males present at older age, with a greater comorbidity index, at later stages of disease. Increased education regarding the continued risks of male breast cancer may be warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.